Clinical trials: Allergic Rhinoconjunctivitis
Rhino-conjunctivitis
Comparison of Different Up-dosing Schedules With Osiris Phleum Pratense
The purpose of this trial is to investigate the tolerability of Osiris Phleum pratense used with 2 simplified up-dosing schedules compared to the up-dosing schedule used in current practice.
- Trial name
- Osiris (NCT01425788)
- Testing
- Osiris Phleum pratense
- Where
- Poland
- Volunteers
- 236 people
- Sponsor
- ALK-Abelló A/S
Dust Mite Allergy, Allergic Rhinitis
Impact of a Novel Immune Modulating Dietary Supplement on House Dust Mite Induced Allergic Rhinoconjunctivitis
A validated mobile Allergen exposure chamber (AEC) is used to expose qualified study participants suffering from house dust mite (HDM) induced allergic rhinoconjunctivitis.
- Trial name
- NCT04477382
- Testing
- holo-BLG (beta-lactoglobulin) - a major component of the protein fraction of raw milk, is loaded with ligands such as retinoic acid, zinc and polyphenol-iron complexes.
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Ecarf Institute GmbH
House Dust Mite Allergy
Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients
hdmASIT+TM product is based on highly purified allergen fragments from house dust mites. The purpose of this study is to assess the safety and clinical tolerability of subcutaneous immunotherapy with hdmASIT+TM in patients with…
- Trial name
- NCT03094845
- Testing
- hdmASIT+TM
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- ASIT Biotech S.A.
Allergic Rhinoconjunctivitis
Efficacy and Safety of Lertal® as an add-on to Standard Therapy for Allergic Rhinoconjunctivitis in Pediatrics
The purpose of this study is to evaluate the efficacy and safety of Lertal® as an add-on treatment for children affected by allergic rhinoconjunctivitis.
- Trial name
- NCT03365648
- Testing
- Lertal® + standard therapy
- Where
- 17 sites in Italy
- Volunteers
- 150 people
- Sponsor
- NTC srl
Rhinitis, Allergic, Conjunctivitis
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)
This study will evaluate the efficacy and safety of ragweed sublingual tablet (SCH 39641/MK-3641/Amb a 1-U) compared with placebo in participants with ragweed-induced rhinoconjunctivitis over a one-year period.
- Trial name
- NCT00770315
- Testing
- Ambrosia artemisiifolia allergen extract (Amb a 1-U)
- Volunteers
- 784 people
- Sponsor
- ALK-Abelló A/S
Allergy
Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy
The primary objective of this study is to demonstrate that SLIT administered pre-and co-seasonally is effective in reducing rhinoconjunctivitis symptoms during the entire short ragweed pollen season.
- Trial name
- NCT01353079
- Testing
- Short Ragweed Pollen Allergenic Extract
- Where
- United States
- Volunteers
- 429 people
- Sponsor
- Greer Laboratories
Birch Pollen-related Rhinoconjunctivitis, Rhinitis, Allergic, Seasonal
Study of rBet v1 Tablets
The purpose of this study is to determine the efficacy and safety of three doses of r Bet v1 administered as sublingual tablets in birch pollen allergic subjects.
- Trial name
- NCT00901914
- Testing
- rBet v 1
- Where
- 8 sites in Denmark, Finland and 6 more
- Volunteers
- 483 people
- Sponsor
- Stallergenes Greer
Grass Pollen Allergy, Hay Fever
Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis
The purpose of the study is to evaluate the efficacy and safety of grass pollen-derived peptides administrated orally to treat seasonal allergic rhinoconjunctivitis.
- Trial name
- NCT01308021
- Testing
- gpASIT+TM
- Where
- 19 sites in Belgium, France and 1 more
- Volunteers
- 202 people
- Sponsor
- BioTech Tools S.A.
Birch Pollen-Related Rhinoconjunctivitis, Rhinitis, Allergic, Seasonal
Safety and Tolerability Study of rBet v1 SLIT Tablets
The purpose of this study is to determine the safety and tolerability of several doses of r Bet v1 administered as sub-lingual tablets in subjects sensitised to birch pollen.
- Trial name
- NCT00889460
- Testing
- rBet v 1
- Where
- Denmark
- Volunteers
- 55 people
- Sponsor
- Stallergenes Greer
Allergic Rhinitis/Rhinoconjunctivitis +-Intermittent Asthma, Sensitization Against Betula Alba (Birch) Pollen
Depigoid Birch 5000 Longterm Study in Adults and Adolescents
Specific immunotherapy for IgE mediated sensitization to birch pollen. Long-term study to assess safety and efficacy of Depigoid(R)Birch 5000 - a modified pollen extract of Betula alba (Birch) - versus placebo.
- Trial name
- NCT01694836
- Testing
- s.c. injection
- Where
- 2 sites in Germany
- Volunteers
- 634 people
- Sponsor
- Leti Pharma GmbH
Seasonal Allergic Rhinitis, Rhinoconjunctivitis
Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen
The PQGrass306 (G306) clinical trial is the pivotal Phase III efficacy clinical trial of PQ Grass. The aim of the G306 pivotal clinical trial is to confirm the efficacy and safety of the optimal effective dose of PQ Grass 27600…
- Trial name
- NCT05540717
- Testing
- PQ Grass
- Where
- 102 sites in United States, Austria and 4 more
- Volunteers
- 555 people
- Sponsor
- Allergy Therapeutics
Rhinoconjunctivitis, Ragweed Allergy
Ragweed-SPIRE Follow-On Study
The purpose of this study is to determine the efficacy of Ragweed-SPIRE 12 months after the initial dose.
- Trial name
- NCT02396680
- Where
- 3 sites in Canada
- Volunteers
- 249 people
- Sponsor
- Circassia Limited
Seasonal Allergic Rhinitis
Evaluating the Efficacy of Ragweed-SPIRE Following Exposure to Ragweed Allergen in an Environmental Exposure Chamber
The purpose of this study is to determine whether Ragweed-SPIRE is safe and effective at reducing allergy symptoms in people who suffer from allergy to Ragweed pollen
- Trial name
- NCT02061709
- Testing
- Ragweed-SPIRE
- Where
- 5 sites in Canada
- Volunteers
- 280 people
- Sponsor
- Circassia Limited
Allergic Conjunctivitis
Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis
The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in the treatment of the signs and symptoms associated with allergic conjunctivitis or rhinoconjunctivitis.
- Trial name
- NCT00331500
- Testing
- Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, Olopatadine Hydrochloride Ophthalmic Solution Vehicle
- Volunteers
- 287 people
- Sponsor
- Alcon Research
Allergic Rhinitis, Allergic Rhinoconjunctivitis
PURETHAL Birch RUSH Study
This study investigates the safety of two up-dosing regimen. The safety of PURETHAL Birch will be evaluated in a rush regimen (maximum dose reached in 3 injections during 3 weeks) compared to the conventional regimen (maximum…
- Trial name
- NCT01918956
- Testing
- PURETHAL Birch, 20.000 AUM/ml
- Where
- 8 sites in Poland
- Volunteers
- 120 people
- Sponsor
- HAL Allergy
Allergic Conjunctivitis, Allergic Rhinitis
Therapeutic Effect of Tacrosolv in Patients With Allergic Rhinoconjunctivitis
Allergic conjunctivitis is one of the most common comorbidities of allergic diseases, especially of allergic rhinitis. Rhinoconjunctivitis is an allergic condition of the nasal mucosa and the eyes.
- Trial name
- NCT04532710
- Testing
- Eye Drops, Solution in Single-Dose Container
- Where
- Austria
- Volunteers
- 64 people
- Sponsor
- Marinomed Biotech AG
Seasonal Allergic Rhinoconjunctivitis
Clinical Safety and Tolerability Study of gpASIT+TM and gpASIT+TM/Immunoregulating Adjuvant to Treat Seasonal Grass Pollen Rhinoconjunctivitis
The purpose of this study is to assess the safety and tolerability of gpASIT+TM administered subcutaneously in absence or in presence of an immunoregulating adjuvant in grass pollen allergic patients.
- Trial name
- NCT01111279
- Testing
- gpASIT+TM, gpAST+TM/adjuvant
- Where
- Belgium
- Volunteers
- 27 people
- Sponsor
- BioTech Tools S.A.
Allergic Rhinoconjunctivitis
Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®
The specific clinical trial is a part in which ALK- Abelló will directly work to explore human immunological mechanisms of SIT (observed after GRAZAX treatment).
- Trial name
- GT-20 (NCT02437786)
- Testing
- GRAZAX
- Where
- Spain
- Volunteers
- 58 people
- Sponsor
- ALK-Abelló A/S
Seasonal Allergic Rhinitis
Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis
The objective of the study is to evaluate the efficacy and tolerability of Bilastine 20 mg, compared to Cetirizine and placebo for the treatment of seasonal allergic rhinitis.
- Trial name
- NCT00504933
- Testing
- bilastine, Cetirizine
- Volunteers
- 683 people
- Sponsor
- Faes Farma, S.A.
Rhinitis Allergic, Conjunctivitis
A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)
This is a study to evaluate the efficacy and safety of grass sublingual tablet (SCH 697243) versus placebo in the treatment of grass pollen-induced allergic hayfever symptoms.
- Trial name
- NCT01385371
- Testing
- Grass (Phleum pratense) pollen allergen extract
- Volunteers
- 1,501 people
- Sponsor
- ALK-Abelló A/S